ديجيتال فابلت

الوسم: Alzheimer’s disease

  • Novel Blood Test Could Foretell Alzheimer’s Risk

    Novel Blood Test Could Foretell Alzheimer’s Risk

    Doctors have long been searching for a straightforward blood test that can predict whether someone is at risk of developing Alzheimer’s disease before noticeable memory loss occurs. Currently, diagnosis often depends on costly or invasive procedures like brain scans or spinal fluid analysis. A dependable blood test could simplify early detection and enable researchers to identify at-risk individuals years before symptoms emerge.

    Researchers from the Mass General Brigham Neuroscience Institute, along with international collaborators, have made significant progress by investigating a blood biomarker called p-tau217. This marker indicates abnormal changes in tau, a protein that deteriorates in Alzheimer’s and contributes to brain cell damage. The findings were presented at the Alzheimer’s Association International Conference and published in JAMA.

    The team analyzed data from six different studies involving 2,684 adults from Australia, Japan, and North America, all of whom initially had healthy memory and cognitive functions. Blood samples were taken to measure p-tau217 levels, and participants underwent PET scans to observe brain changes. Their memory and thinking abilities were monitored annually. Throughout the studies, 478 participants developed cognitive impairments.

    Results showed a distinct pattern: individuals with the highest p-tau217 levels faced a significantly increased risk of progressing to cognitive decline compared to those with lower levels. Specifically, their estimated risk was 38% over five years and 78% after ten years. While the ten-year figures are promising, the researchers note that fewer participants reached that point, so the estimates are less precise.

    An important discovery was that p-tau217 remained a valuable predictor even after considering other major Alzheimer’s risk factors like amyloid plaque buildup and genetics. This suggests the blood test may offer unique insights beyond existing diagnostic methods.

    Despite these encouraging results, researchers advise caution against widespread testing in healthy people at this stage. Senior author Dr. Reisa Sperling explained that knowing someone is at high risk doesn’t currently alter medical treatment options since effective preventative therapies are limited. Maintaining healthy habits—regular exercise, good nutrition, quality sleep, and managing blood pressure and diabetes—remains the best approach for supporting brain health.

    The researchers believe the utility of the p-tau217 test could grow substantially if ongoing prevention trials prove successful. Eventually, clinicians might use p-tau217 screening to identify individuals who could benefit from emerging treatments before irreversible brain damage occurs.

    As with all research, this study has limitations. Participants were volunteers involved in specific projects and might not fully represent the general population. Longer-term studies are needed to assess risk over decades rather than just several years.

    Overall, these findings bring us closer to a future where Alzheimer’s risk can be gauged through a simple blood test instead of complex and invasive procedures. Although routine screening is not imminent, this research offers a solid scientific step toward proactive prevention.

    If you’re interested in Alzheimer’s, consider exploring studies about its suspected causes and new non-drug therapies that could help prevent the disease. For more health insights, look into recent research on diets that may lower Alzheimer’s risk and lifestyle changes that might help prevent some cases of dementia.

  • New Blood Test Could Detect Alzheimer’s Risk Early

    New Blood Test Could Detect Alzheimer’s Risk Early

    Alzheimer’s disease is the leading cause of dementia, impacting millions of seniors worldwide. It gradually destroys brain cells, leading to memory loss, confusion, and difficulties with thinking and daily activities. Experts understand that brain changes begin years before symptoms show.

    For this reason, scientists have been exploring simple ways to identify individuals at high risk long before noticeable memory issues develop. One promising method is a blood test that detects a protein called phosphorylated tau 217, or p-tau217. Normally, tau proteins are present in the brain, but in Alzheimer’s, they become abnormal and form tangles that harm brain tissue.

    Recently, a blood test measuring p-tau217 gained approval from U.S. regulators, sparking hope that it could serve as an accessible tool for detecting Alzheimer’s-related brain changes without expensive scans. A new international study led by researchers at the Mass General Brigham Neuroscience Institute evaluated how well this blood test predicts future memory decline in cognitively healthy individuals.

    Data from six studies across North America, Australia, and Japan was pooled, including 2,684 older adults with normal mental function. All participants provided blood samples for p-tau217 testing and underwent PET scans of the brain at the start. They also completed annual assessments of memory and thinking. Some had been followed since 2004, with the latest evaluations extending into 2025.

    During the study, 478 participants developed cognitive impairment. Results showed that those with very high p-tau217 levels had a significantly increased risk of future memory and thinking problems. Their chances reached 38% within five years and climbed to 78% over ten years, though the long-term estimate should be interpreted cautiously due to fewer participants at that stage.

    Crucially, the blood test predicted future risk even after accounting for other known factors like amyloid plaques seen on PET scans and genetic risk factors such as the APOE4 gene variant. This suggests p-tau217 might provide unique insights beyond existing diagnostic tools.

    Despite these promising findings, researchers emphasize that the blood test isn’t currently recommended for healthy individuals without symptoms. Limited treatment options mean that simply knowing your risk doesn’t yet change medical management. Dr. Reisa Sperling, the study’s senior author, advised that current recommendations remain unchanged: stay physically active, maintain a healthy diet, get quality sleep, and prioritize overall wellness.

    This may change in the future if prevention trials succeed with new treatments that can delay or prevent Alzheimer’s. Blood tests like p-tau217 could then help identify who might benefit most from early intervention and closer monitoring.

    The study has some limitations. Most participants were drawn from research cohorts rather than the general population, which might limit how broadly the results apply. Longer follow-up is needed to better understand lifetime risk, beyond the five- and ten-year estimates.

    Overall, this research marks a big step toward tailored Alzheimer’s risk prediction. It highlights the potential of a simple blood test to help doctors estimate an individual’s future risk—similar to how cholesterol tests predict heart disease risk. More research will be necessary before such testing becomes routine for healthy adults.

    If you’re interested in Alzheimer’s prevention, consider reading about how dietary antioxidants may protect against the disease, or how specific eating habits might influence risk. Recent studies also suggest that oral cannabis extracts could help reduce symptoms, and vitamin E might play a role in preventing Parkinson’s disease.

    Source: Mass General Brigham.

  • Rosemary Compound Shows Promise as Alzheimer’s Treatment

    Rosemary Compound Shows Promise as Alzheimer’s Treatment

    A natural compound found in common herbs like rosemary and sage may hold promise for future Alzheimer’s treatments. Researchers have developed a more stable version of this plant-derived substance, which has shown the ability to enhance memory and minimize brain damage in animal models of Alzheimer’s disease. While the research is still in its early phases, these findings have sparked optimism among scientists about the potential for safer, more effective therapies down the line.

    This study was conducted by scientists at Scripps Research and published in the journal Antioxidants.

    Alzheimer’s disease is the leading cause of dementia, a condition characterized by a decline in memory, thinking skills, language ability, and daily functioning. Over years, it progressively destroys brain cells, making it increasingly difficult for affected individuals to remember recent events, recognize loved ones, solve problems, or live independently. With millions worldwide impacted and numbers rising due to increased longevity, the quest for better treatments remains urgent.

    Currently, most medications only help manage symptoms temporarily and do not halt the disease’s progression. Newer drugs aimed at removing harmful brain proteins show promise but often come with serious side effects and are not universally effective. As a result, researchers continue to explore various strategies for brain protection.

    Historically, rosemary has been associated with memory and remembrance, even symbolized by William Shakespeare. Scientists have recently identified that rosemary and sage contain a natural compound called carnosic acid. This substance functions as both an antioxidant, protecting cells from damage, and an anti-inflammatory, reducing long-lasting tissue inflammation. Brain inflammation is increasingly recognized as a significant contributor to Alzheimer’s disease, as it damages neurons and weakens synapses—the tiny junctions between brain cells that facilitate communication vital for learning and memory.

    Despite its potential benefits, carnosic acid faces a key challenge: it is highly unstable. It tends to break down rapidly when exposed to air or during storage, complicating efforts to develop it into a drug. To address this, the Scripps team engineered a new compound called diAcCA. This stable form remains intact during storage but converts back into active carnosic acid once ingested. After swallowing, diAcCA is processed in the digestive system, enters the bloodstream, and travels to the brain where it exerts its effects.

    In tests using mice engineered to exhibit Alzheimer’s-like symptoms, diAcCA produced promising results. Treated animals performed significantly better on memory tests compared to untreated counterparts, with some approaching normal memory function. Brain analyses revealed increased connectivity between neurons, reduced inflammation, and lowered levels of amyloid-beta plaques and phosphorylated tau proteins—two hallmarks of Alzheimer’s pathology.

    Interestingly, diAcCA also facilitated greater absorption of the active compound—about 20% more than direct intake of carnosic acid—meaning more of the therapeutic agent reaches the brain. Importantly, safety assessments showed no signs of toxicity, and the compound even appeared to lower inflammation in the digestive tract, hinting at additional health benefits.

    Dr. Stuart Lipton, the lead researcher, noted that diAcCA’s main advantage lies in its targeted activation, primarily in inflamed areas of the brain. This selectivity could help shield healthy tissue from unnecessary exposure, reducing potential side effects. Because carnosic acid has a well-established safety record in humans, scientists are optimistic that the path to clinical trials might be quicker than for novel drugs.

    Nonetheless, extensive testing in human subjects remains essential to confirm safety and effectiveness. Researchers also see potential for this compound to be studied in connection with other inflammation-related conditions, such as Parkinson’s disease, type 2 diabetes, and cardiovascular diseases.

    Though it’s too early to suggest rosemary can prevent or cure Alzheimer’s, this research underscores how natural plant compounds can inspire innovative medicines. By combining traditional botanical benefits with modern drug technology, scientists are paving the way for new treatments that could better safeguard the aging brain.

    For those interested in brain health, ongoing studies also explore links between vitamin D deficiency and Alzheimer’s, as well as possible benefits of oral cannabis extracts in reducing symptoms. Additional research examines how vitamin B9 deficiency correlates with increased dementia risk, and how flavonoid-rich diets could improve survival rates in Parkinson’s disease.

    © 2026 Knowridge Science Report. All rights reserved.

  • Unexpected Breakfast Food Could Reduce Alzheimer’s Risk

    Unexpected Breakfast Food Could Reduce Alzheimer’s Risk

    Credit: Unsplash+

    Alzheimer’s disease ranks among the most significant health challenges faced by older adults worldwide.

    The condition gradually impairs memory, cognition, and daily functioning, often rendering individuals unable to live independently.

    Families are deeply impacted, witnessing loved ones slowly forget important events, recognize familiar people, or handle everyday tasks.

    Researchers have dedicated years to understanding what factors increase the risk of Alzheimer’s and what measures might help reduce it. While age and genetics are key elements, lifestyle choices—such as physical activity, sleep quality, and diet—are believed to influence brain health over time.

    A recent study from Loma Linda University Health proposes that consuming eggs regularly could potentially lower the risk of Alzheimer’s disease in older adults.

    Guided by Dr. Joan Sabaté, a professor at the Loma Linda University School of Public Health, the study was published in the Journal of Nutrition.

    The findings suggest that individuals aged 65 and above who regularly eat eggs have a decreased likelihood of developing Alzheimer’s compared to those who seldom or never include eggs in their diet.

    The study indicates that eating at least one egg daily for five or more days each week could be associated with up to a 27% reduction in Alzheimer’s risk.

    Even smaller amounts of egg intake appeared beneficial. Those who consumed eggs one to three times a month had around a 17% lower risk, while eating eggs two to four times weekly correlated with approximately a 20% decreased risk, compared to non-eaters.

    This research utilized data from the Adventist Health Study-2, a large-scale, long-term project involving roughly 40,000 participants. Researchers linked participants’ health records with Medicare data to identify Alzheimer’s diagnoses confirmed by doctors.

    Participants were followed for an average of over 15 years, offering a comprehensive view of how long-term dietary habits might impact brain health.

    The scientific community chose to examine eggs because there remains much to learn about how diet influences Alzheimer’s risk. While many foods have been studied concerning heart health and weight management, understanding their effect on brain aging is an ongoing effort.

    Eggs gained attention due to their rich nutrient profile, which may support brain function. Notably, they contain choline, a nutrient essential for producing acetylcholine—a chemical messenger crucial for memory and neuron communication, both of which are affected in Alzheimer’s.

    Eggs also contain lutein and zeaxanthin, carotenoids that can accumulate in brain tissue and potentially mitigate oxidative stress—a damaging process linked to aging and neurodegeneration.

    Furthermore, eggs provide omega-3 fatty acids and phospholipids, which play roles in maintaining healthy brain cell membranes and ensuring effective nerve signaling.

    The study considered different forms of egg consumption, including cooked dishes like scrambled, boiled, and fried eggs, as well as eggs incorporated into baked goods and processed foods.

    Researchers emphasized that their findings don’t suggest eggs are a cure-all for Alzheimer’s. Instead, they highlight that eggs could be part of a broader, healthy dietary pattern.

    It’s also important to note that many participants in the Adventist Health Study tend to lead healthier lifestyles—favoring plant-based diets, abstaining from smoking, and exercising regularly—that could influence the findings.

    Dr. Jisoo Oh, a lead researcher, noted that overall healthy living should be the focus, rather than relying solely on one food item.

    The results support growing evidence that nutrition plays a role in brain aging. Researchers increasingly believe that diet over many years affects inflammation, blood flow, oxidative balance, and neuron communication in the brain.

    While promising, scientists caution that this type of observational research can’t definitively establish cause and effect. The link between egg consumption and reduced Alzheimer’s risk is just an association, not proof that eggs prevent the disease.

    Other lifestyle factors—such as physical activity, quality of sleep, education, social interactions, and overall diet quality—also contribute to cognitive health outcomes.

    The study adds to the expanding body of evidence suggesting that certain nutrients in eggs may support brain function as we age.

    These findings could also reassure those who have avoided eggs due to concerns about cholesterol, especially since many nutrition experts now believe that moderate egg intake can fit into a balanced diet for most people.

    Future research may shed more light on how eggs and their nutrients influence brain health and identify which groups could benefit most.

    For now, adopting a comprehensive approach—focused on healthy habits like balanced eating, physical activity, managing blood pressure and diabetes, adequate sleep, social engagement, and mental activity—seems most effective for protecting brain health long-term.

    If Alzheimer’s prevention interests you, explore studies linking vitamin D deficiency to Alzheimer’s, vascular dementia, and the potential benefits of oral cannabis extracts in reducing symptoms.

    Additional research highlights the importance of vitamin B9, with recent findings suggesting that diets rich in flavonoids might improve survival rates in Parkinson’s disease.

  • Alzheimer’s Gene May Weaken Bones in Women

    Alzheimer’s Gene May Weaken Bones in Women

    Scientists are discovering that the human body is more interconnected than we previously believed. A recent study conducted by the Buck Institute for Research on Aging, in collaboration with researchers from the University of California, San Francisco, has revealed an unexpected link between brain health and bone strength.

    Published in the journal Advanced Science, the research centers around a gene called APOE4, already recognized as the strongest genetic risk factor for Alzheimer’s disease. Alzheimer’s is a neurodegenerative disorder that gradually impairs memory and cognition, predominantly affecting older adults. Women are notably more susceptible to developing the disease than men.

    For years, clinicians have observed that individuals with Alzheimer’s often have weaker bones and a higher likelihood of fractures. Bone loss in women has even been considered an early warning sign before the onset of Alzheimer’s, yet the underlying reasons remained unclear. To investigate this, scientists used mice genetically engineered to carry human variants of the APOE gene—namely APOE2, APOE3, and APOE4—focusing on how these variants influence both brain and bone health simultaneously.

    The findings were striking. Female mice with the APOE4 gene exhibited significant deterioration in bone quality, despite presenting as normal in typical imaging scans. This suggests that conventional tests might overlook early-stage damage occurring deep within the bones at a microscopic level. The researchers identified that osteocytes—specialized cells responsible for maintaining bone integrity—were functioning improperly. These cells sustain tiny channels inside bones that are crucial for preserving strength and flexibility. When osteocytes fail to operate correctly, bones weaken even if they appear structurally normal externally.

    Further analysis revealed that APOE4 disrupts the maintenance functions of osteocytes, impairing their ability to repair and sustain bone tissue. This leads to the gradual accumulation of unseen damage. Notably, this effect was more pronounced in females, aligning with clinical observations that women face a higher risk of both osteoporosis and Alzheimer’s.

    An additional discovery was that bones harbor numerous proteins also associated with brain disorders. This points to bones potentially reflecting early signs of neurological changes—sometimes even more prominently than brain tissue itself. Such protein alterations could serve as useful biomarkers for early diagnosis.

    These insights pave the way for novel approaches to early detection. If bone changes can be identified before cognitive symptoms manifest, it could enable earlier intervention to slow or prevent disease progression. Furthermore, targeting bone cells for protective therapies might offer dual benefits, safeguarding both skeletal health and brain function.

    It’s important to note, however, that these results are based on animal models. While promising, further research is essential to determine if similar processes occur in humans. Scientists also need to develop safe, effective methods to target these mechanisms.

    Overall, this study emphasizes the importance of viewing the human body as a complex, interconnected system. It demonstrates that genes linked to brain diseases can have hidden effects on other tissues, especially in women. Although additional studies are required, these findings could lead to innovative strategies for early detection and management of Alzheimer’s disease.

    For those interested in brain health, exploring research on vitamin D deficiency’s connection to Alzheimer’s and vascular dementia, as well as the potential benefits of magnesium, is recommended. Keeping informed about antioxidants that may help lower dementia risk and understanding how nutrients like coconut oil could support cognitive functions may also be valuable.